GEROPHARM obtains the Made in Russia certificate for insulin glargine. It is the world's most widely used basal insulin analogue and one of the most exported insulins in the company's portfolio. GEROPHARM has already obtained marketing authorisations for insulin glargine in Azerbaijan, Venezuela, Kazakhstan, Cuba, Uzbekistan and other countries. And in early June, the medicinal product was also registered in Morocco.
The award ceremony took place on June 15 as part of the SPIEF. GEROPHARM was represented by Roman Drai, Director of Research & Development Center.
The trademark assignment certificate proves the quality of the products offered by reliable Russian companies that boast innovative solutions and a great export potential. The Made in Russia certification is an excellent opportunity for businesses to promote their innovations along with unique and high-quality products and services. Certified products will be promoted at international exhibitions, business missions and advertising projects focusing on foreign markets. This certification system helps the target audience evaluate the quality and competitiveness of products made in Russia.
“For us, export is one of the top priorities of business development. Today, we supply insulin in dosage forms while also localising its production abroad. GEROPHARM focuses on global expansion, especially to the countries of Latin America, Southeast Asia, the Middle East, North Africa and the Persian Gulf,” Roman noted.